DBV Technologies' (DBVT) Market Outperform Rating Reaffirmed at JMP Securities

DBV Technologies (NASDAQ:DBVT - Get Free Report)'s stock had its "market outperform" rating reaffirmed by investment analysts at JMP Securities in a report released on Thursday,Benzinga reports. They currently have a $21.00 target price on the stock. JMP Securities' price objective would indicate a potential upside of 128.63% from the stock's current price.

DBVT has been the topic of a number of other reports. HC Wainwright increased their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a report on Monday, May 5th. Wall Street Zen raised shares of DBV Technologies from a "sell" rating to a "hold" rating in a research note on Friday, May 9th. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 target price on the stock in a research note on Thursday, May 29th. Finally, Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $14.75.

DBV Technologies Trading Down 0.3%

Shares of DBV Technologies stock traded down $0.03 on Thursday, reaching $9.19. The stock had a trading volume of 12,742 shares, compared to its average volume of 191,385. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $12.78. The company has a market cap of $251.58 million, a P/E ratio of -1.87 and a beta of -0.63. The business's 50 day moving average is $9.24 and its two-hundred day moving average is $6.32.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. DBV Technologies had a negative return on equity of 278.24% and a negative net margin of 3,249.99%. The firm had revenue of $0.51 million during the quarter. On average, equities analysts anticipate that DBV Technologies will post -7.05 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.